Main Appendix: Appendix 1: Glossary Clostridium difficile infection (CDI) - Symptomatic infection caused by the spore-forming, bacterium, Clostridium difficile. It is the most common cause of antibiotic-associated diarrhoea, and symptoms include watery stools, fever, nausea, and abdominal pain. Refractory CDI – Failure of an episode of CDI to respond to metronidazole and oral vancomycin, although no uniform definition. Recurrent CDI – Defined in ESMID guidelines as ‘when CDI re-occurs within 8 weeks after the onset of a previous episode, provided the symptoms from the previous episode resolved after completion of initial treatment’[4]; however, defined more variably within the reviewed literature within this guideline. Faecal microbiota transplant – A procedure in which faecal matter (stool) is collected from a healthy screened donor, homogenised, strained, and introduced into the gastrointestinal tract of a patient. Donor – In the context of FMT, this is a healthy screened individual that provides stool for the use in preparation of FMT. Nasogastric – A means of reaching/ supplying the stomach via the nose for the purpose of treatment or investigation. This is usually achieved by the insertion of a tube. Enema – A procedure in which liquid (or gas) is infused into the rectum as means for treatment or investigation. Gut microbiota - Population of microorganisms that live in the gastrointestinal tract including bacteria, viruses and fungi. Inflammatory bowel disease – Describes a group of chronic disorders (ulcerative colitis and Crohn’s diseases) in which the gastrointestinal tract becomes inflamed. The exact cause is unknown but it is thought to result from a combination of factors that trigger the body’s immune system to produce an inflammatory reaction in the gastrointestinal tract. Medicines and Healthcare Products Regulatory Agency - An executive agency of the Department of Health in the United Kingdom which is responsible for ensuring that medicines and medical devices are efficacious and are acceptably safe.
Main Appendix: Appendix 1: Glossary Clostridium difficile infection (CDI) - Symptomatic infection caused by the spore-forming, bacterium, Clostridium difficile. It is the most common cause of antibiotic-associated diarrhoea, and symptoms include watery stools, fever, nausea, and abdominal pain. Refractory CDI – Failure of an episode of CDI to respond to metronidazole and oral vancomycin, although no uniform definition. Recurrent CDI – Defined in ESMID guidelines as ‘when CDI re-occurs within 8 weeks after the onset of a previous episode, provided the symptoms from the previous episode resolved after completion of initial treatment’[4]; however, defined more variably within the reviewed literature within this guideline. Faecal microbiota transplant – A procedure in which faecal matter (stool) is collected from a healthy screened donor, homogenised, strained, and introduced into the gastrointestinal tract of a patient. Donor – In the context of FMT, this is a healthy screened individual that provides stool for the use in preparation of FMT. Nasogastric – A means of reaching/ supplying the stomach via the nose for the purpose of treatment or investigation. This is usually achieved by the insertion of a tube. Enema – A procedure in which liquid (or gas) is infused into the rectum as means for treatment or investigation. Gut microbiota - Population of microorganisms that live in the gastrointestinal tract including bacteria, viruses and fungi. Inflammatory bowel disease – Describes a group of chronic disorders (ulcerative colitis and Crohn’s diseases) in which the gastrointestinal tract becomes inflamed. The exact cause is unknown but it is thought to result from a combination of factors that trigger the body’s immune system to produce an inflammatory reaction in the gastrointestinal tract. Medicines and Healthcare Products Regulatory Agency - An executive agency of the Department of Health in the United Kingdom which is responsible for ensuring that medicines and medical devices are efficacious and are acceptably safe.
fmt-appendices-1-4.docx